Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Total Non-Current Liabilities: 2020-2022

Historic Total Non-Current Liabilities for Caribou Biosciences (CRBU) over the last 1 years, with Mar 2022 value amounting to $74.2 million.

  • Caribou Biosciences' Total Non-Current Liabilities was N/A to $74.2 million in Q1 2022 from the same period last year, while for Mar 2022 it was $74.2 million, marking a year-over-year change of. This contributed to the annual value of $54.5 million for FY2021, which is 203.12% up from last year.
  • Latest data reveals that Caribou Biosciences reported Total Non-Current Liabilities of $74.2 million as of Q1 2022, which was up 36.10% from $54.5 million recorded in Q4 2021.
  • Caribou Biosciences' Total Non-Current Liabilities' 5-year high stood at $74.2 million during Q1 2022, with a 5-year trough of $18.0 million in Q4 2020.
  • Moreover, its 3-year median value for Total Non-Current Liabilities was $55.8 million (2021), whereas its average is $52.0 million.
  • Data for Caribou Biosciences' Total Non-Current Liabilities shows a peak YoY soared of 203.12% (in 2021) over the last 5 years.
  • Over the past 3 years, Caribou Biosciences' Total Non-Current Liabilities (Quarterly) stood at $18.0 million in 2020, then skyrocketed by 203.12% to $54.5 million in 2021, then reached $74.2 million in 2022.
  • Its Total Non-Current Liabilities stands at $74.2 million for Q1 2022, versus $54.5 million for Q4 2021 and $57.4 million for Q3 2021.